CN104144708B - 基于脂质的纳米粒子 - Google Patents

基于脂质的纳米粒子 Download PDF

Info

Publication number
CN104144708B
CN104144708B CN201280017548.6A CN201280017548A CN104144708B CN 104144708 B CN104144708 B CN 104144708B CN 201280017548 A CN201280017548 A CN 201280017548A CN 104144708 B CN104144708 B CN 104144708B
Authority
CN
China
Prior art keywords
liposome composition
lipid
imaging
formula
hydrophilic polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280017548.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104144708A (zh
Inventor
A·安娜普拉戈达
J·L·艾瑞克森
E·A·塔尼夫姆
I·达斯格普塔
S·C·库克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A Erzi Card Biological Science Co Ltd
System Board Of Directors Of University Of Houston
University of Texas System
Original Assignee
A Erzi Card Biological Science Co Ltd
System Board Of Directors Of University Of Houston
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104144708(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A Erzi Card Biological Science Co Ltd, System Board Of Directors Of University Of Houston, University of Texas System filed Critical A Erzi Card Biological Science Co Ltd
Publication of CN104144708A publication Critical patent/CN104144708A/zh
Application granted granted Critical
Publication of CN104144708B publication Critical patent/CN104144708B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
CN201280017548.6A 2011-04-06 2012-04-06 基于脂质的纳米粒子 Expired - Fee Related CN104144708B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
US61/472,605 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Publications (2)

Publication Number Publication Date
CN104144708A CN104144708A (zh) 2014-11-12
CN104144708B true CN104144708B (zh) 2017-07-28

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280017548.6A Expired - Fee Related CN104144708B (zh) 2011-04-06 2012-04-06 基于脂质的纳米粒子

Country Status (14)

Country Link
US (1) US9801957B2 (OSRAM)
EP (2) EP2694116B1 (OSRAM)
JP (3) JP6212032B2 (OSRAM)
KR (2) KR101973063B1 (OSRAM)
CN (1) CN104144708B (OSRAM)
AU (3) AU2012239888B9 (OSRAM)
BR (1) BR112013025633A2 (OSRAM)
CA (1) CA2831480C (OSRAM)
DK (1) DK2694116T3 (OSRAM)
ES (1) ES2685824T3 (OSRAM)
MX (1) MX357227B (OSRAM)
PL (1) PL2694116T3 (OSRAM)
PT (1) PT2694116T (OSRAM)
WO (1) WO2012139080A2 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831480C (en) * 2011-04-06 2020-09-29 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
AU2013209437B2 (en) 2012-01-20 2018-07-12 Ananth Annapragada Methods and compositions for objectively characterizing medical images
US9512092B2 (en) 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
ES3032054T3 (en) * 2014-10-08 2025-07-15 Texas Childrens Hospital Mri imaging of amyloid plaque using liposomes
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
PL3458074T3 (pl) * 2016-05-16 2024-11-12 Board Of Regents Of The University Of Texas System KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
WO2018100540A1 (en) * 2016-11-30 2018-06-07 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
US20200261605A1 (en) * 2019-01-24 2020-08-20 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
KR102546470B1 (ko) * 2020-01-29 2023-06-21 텍사스 칠드런스 하스피탈 아밀로이드 침착의 mri용 표적 조영제
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
EP4103239A4 (en) * 2020-02-12 2024-03-20 Texas Children's Hospital TARGETED CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING OF ALPHA-SYNUCLEIN DEPOSITS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
IL113139A0 (en) 1994-03-28 1995-06-29 Nycomed Imaging As Diagnostic compositions comprising imaging agents encapsulated in liposomes
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
EP1233752B1 (en) 1999-11-30 2005-01-26 The Arizona Board of Regents on behalf of The University of Arizona Radiation sensitive liposomes
AU2002211517A1 (en) * 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
AU2002314794A1 (en) * 2001-05-23 2002-12-03 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
WO2003075977A2 (en) 2002-03-05 2003-09-18 Cleveland State University Agglomerated particles for aerosol drug delivery
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
WO2006032705A2 (en) * 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
WO2008054498A2 (en) * 2006-04-07 2008-05-08 The Board Of Trustees Of The University Of Illinois Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
CA2695204A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
WO2009073236A1 (en) 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
AU2009257279A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JP2012520898A (ja) 2009-03-19 2012-09-10 マーヴァル バイオサイエンシーズ，インコーポレイテッド 画像化におけるコントラスト強調のための組成物および方法
US9334304B2 (en) * 2009-04-02 2016-05-10 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
DK2582674T3 (en) 2010-06-16 2014-12-15 Cymabay Therapeutics Inc GPR120 receptor agonists and uses thereof.
ES2913069T3 (es) 2011-03-02 2022-05-31 Sensulin Llc Composiciones de vesículas
CA2831480C (en) * 2011-04-06 2020-09-29 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
AU2013209437B2 (en) 2012-01-20 2018-07-12 Ananth Annapragada Methods and compositions for objectively characterizing medical images
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
ES3032054T3 (en) 2014-10-08 2025-07-15 Texas Childrens Hospital Mri imaging of amyloid plaque using liposomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions

Also Published As

Publication number Publication date
KR20190031334A (ko) 2019-03-25
PT2694116T (pt) 2018-10-12
KR102035187B1 (ko) 2019-11-08
AU2012239888A2 (en) 2014-05-08
CA2831480C (en) 2020-09-29
EP2694116A2 (en) 2014-02-12
KR20140074868A (ko) 2014-06-18
WO2012139080A2 (en) 2012-10-11
EP3366313A1 (en) 2018-08-29
CA2831480A1 (en) 2012-10-11
EP2694116B1 (en) 2018-06-13
CN104144708A (zh) 2014-11-12
ES2685824T3 (es) 2018-10-11
AU2012239888B9 (en) 2017-10-12
US20120258044A1 (en) 2012-10-11
AU2019246775A1 (en) 2019-10-31
BR112013025633A2 (pt) 2017-08-08
JP6533813B2 (ja) 2019-06-19
AU2012239888A1 (en) 2013-11-07
AU2017232156A1 (en) 2017-10-12
JP2019151664A (ja) 2019-09-12
AU2017232156B2 (en) 2019-07-11
PL2694116T3 (pl) 2018-12-31
KR101973063B1 (ko) 2019-04-30
US9801957B2 (en) 2017-10-31
JP2014523854A (ja) 2014-09-18
DK2694116T3 (en) 2018-09-03
JP2018035167A (ja) 2018-03-08
WO2012139080A3 (en) 2014-05-01
AU2017232156C1 (en) 2019-10-24
AU2012239888B2 (en) 2017-06-22
MX2013011231A (es) 2015-03-05
HK1203827A1 (en) 2015-11-06
MX357227B (es) 2018-07-02
JP6212032B2 (ja) 2017-10-18
EP2694116A4 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
CN104144708B (zh) 基于脂质的纳米粒子
Liu et al. ScFv-conjugated superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of Parkinson’s and Huntington’s diseases
JP6505235B2 (ja) リポソームを用いるアミロイド斑のｍｒｉイメージング
US8349293B2 (en) Use of metal nanoparticles in the diagnosis of Alzheimer's disease
Lacerda et al. Metal complexes for multimodal imaging of misfolded protein-related diseases
US10124078B2 (en) Lipid-based nanoparticles
CN113453666A (zh) 用于肿瘤细胞的选择性成像的融合脂质体
HK1203827B (en) Lipid-based nanoparticles
Andreozzi The Development of Multimodal Imaging Probes for Visualizing Neuroinflammation in Alzheimer's Disease and Traumatic Brain Injury
HK40048059B (zh) 作为用於通过磁共振成像检测β-淀粉样斑的造影剂的与萘衍生物缀合的金属氧化物纳米粒
Zhang Gd-DOTA-anti-Aβ42-F (ab’) 2-antibody fragment (putrescine) n GdAβ42
BR112017007238B1 (pt) Composição lipossomal compreendendo um conjugado fosfolipídiopolímero-aromático e um agente potencializador de contraste de imagem de ressonância magnética não radioativo para geração de imagem de depósitos amiloides
HK1243335B (zh) 使用脂质体进行的淀粉样蛋白斑mri成像

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203827

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1203827

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170728

Termination date: 20200406

CF01 Termination of patent right due to non-payment of annual fee